Compare Sequential and Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea

• Status: Completed
• Trial end date: 2016-04-01
• Target enrollment: 0
• Participant gender: All

Summary

1. To compare 10-day sequential therapy and 14-day modified bismuth quadruple therapy and to establish more effective first-line regimen for the eradication of Helicobacter pylori in Korea.

2. To evaluate the effect of H. pylori eradication therapy on the symptom improvement of functional dyspepsia

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Bundang Hospital
• Collaborators: Chong Kun Dang Pharmaceutical; CJ HealthCare Corporation; Green Cross Corporation; HK inno.N Corporation; SK Chemicals Co., Ltd.; SK Chemicals Co.,Ltd.
• Treatments: Amoxicillin; Bismuth; Clarithromycin; Metronidazole; Pantoprazole; Tetracycline

Criteria

Inclusion Criteria:

• Male and female Korean Adult (Aged ≥ 18 years)

• Patients who diagnosis of H. pylori infection by any of following three methods

• positive rapid urease test (CLOtest)

• histologic evidence of H. pylori by modified Giemsa staining

• positive 13C-urea breath test

Exclusion Criteria:

• Age under 18 years

• Previous eradication treatment for H. pylori

• Patients who took any drug which could influence the study results such as proton pump inhibitor, H2 blocker, mucosal protective agent and antibiotics

• History of gastrectomy

• Advanced gastric cancer or other malignancy

• Abnormal liver function or liver cirrhosis

• Abnormal renal function or chronic kidney disease

• Other severe concurrent diseases

• Previous allergic reactions to the study drugs

• Pregnant or lactating women